(NASDAQ: APGE) Apogee Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.57%.
Apogee Therapeutics's earnings in 2026 is -$255,843,000.On average, 19 Wall Street analysts forecast APGE's earnings for 2026 to be -$337,163,264, with the lowest APGE earnings forecast at -$385,420,768, and the highest APGE earnings forecast at -$275,571,541. On average, 19 Wall Street analysts forecast APGE's earnings for 2027 to be -$399,852,854, with the lowest APGE earnings forecast at -$653,036,248, and the highest APGE earnings forecast at -$321,021,841.
In 2028, APGE is forecast to generate -$471,235,048 in earnings, with the lowest earnings forecast at -$824,637,014 and the highest earnings forecast at -$347,648,588.